HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney.

Abstract
A 5-month-old male with stage II malignant rhabdoid tumor of the kidney (MRTK) and a 24-month-old male with stage III MRTK were treated with surgical resection of tumors and chemotherapy of alternating ICE (ifosfamide, carboplatin, and etoposide) and VDC (vincristine, doxorubicin, and cyclophosphamide), followed by high-dose chemotherapy using etoposide, carboplatin, and melphalan with autologous hematopoietic stem cell transplantation (SCT). Two patients have been alive without any evidence of disease for 30 and 37 months after diagnosis, respectively, and require no medication. Consolidation with SCT should be further studies for selected patients with high-risk MRTK.
AuthorsYuhki Koga, Akinobu Matsuzaki, Aiko Suminoe, Miho Hatano, Yusuke Saito, Yoshiaki Kinoshita, Tatsuro Tajiri, Tomoaki Taguchi, Kenichi Kohashi, Yoshinao Oda, Masazumi Tsuneyoshi, Toshiro Hara
JournalPediatric blood & cancer (Pediatr Blood Cancer) Vol. 52 Issue 7 Pg. 888-90 (Jul 2009) ISSN: 1545-5017 [Electronic] United States
PMID19260106 (Publication Type: Case Reports, Journal Article)
Copyright(c) 2009 Wiley-Liss, Inc.
Chemical References
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Carboplatin
  • Melphalan
  • Ifosfamide
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carboplatin (administration & dosage)
  • Combined Modality Therapy
  • Cyclophosphamide (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Etoposide (administration & dosage)
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Ifosfamide (administration & dosage)
  • Infant
  • Kidney Neoplasms (mortality, pathology, therapy)
  • Male
  • Melphalan (administration & dosage)
  • Prognosis
  • Rhabdoid Tumor (mortality, pathology, therapy)
  • Survival Rate
  • Tomography, X-Ray Computed
  • Transplantation, Autologous
  • Treatment Outcome
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: